Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …

Background We aimed to quantitatively summarise the health economic evaluation
evidence of prevention and control programs addressing COVID-19 globally. Methods We …

Background The COVID-19 outbreak was defined as a pandemic on 11 March 2020 by the
World Health Organization. After that, COVID-19 has enormously influenced health systems …

Summary Background Coronavirus disease 2019 (COVID-19) outbreaks in acute care
settings can have severe consequences for patients due to their underlying vulnerabilities …

Background Remdesivir is being studied and used to treat coronavirus disease 2019
(COVID-19). This study aimed to systematically identify, critically evaluate, and summarize …

Background Of over 8,000 recorded randomised trials addressing COVID-19, around 80%
were of treatments, and 17% have reported results. Approximately 1% were adaptive or …

Introduction Feline Infectious Peritonitis (FIP) has historically been a fatal coronavirus
disease in cats. In recent years, the therapeutic agent GS-441524, developed by Gilead …

Introduction The pathogenesis of severe COVID-19 is due, in part, to dysregulation of the
human immune system in response to SARS-CoV-2 infection. Immune cells infected with …

What do we know about covid in immunocompromised people? | The BMJ Skip to main
content Intended for healthcare professionals Access provided by Google Indexer Subscribe …

Repurposing existing drugs to inhibit SARS-CoV-2 infection in airway epithelial cells (AECs)
is a quick way to find novel treatments for COVID-19. Computational screening has found …